{"id":577,"date":"2018-09-26T11:27:30","date_gmt":"2018-09-26T11:27:30","guid":{"rendered":"https:\/\/credevo.com\/s\/?p=577"},"modified":"2021-05-02T16:15:58","modified_gmt":"2021-05-02T08:15:58","slug":"acute-myeloid-leukemia-aml","status":"publish","type":"post","link":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/","title":{"rendered":"Acute Myeloid Leukemia (AML)"},"content":{"rendered":"<p>Credevo conducted a feasibility on AML (Acute Myeloid Leukemia) and we received a great response from Investigator\/Sites.<\/p>\n<h1>Study details<\/h1>\n<p>The study was Phase 1 &amp; Phase 2, Interventional,&nbsp;Multi-center, Randomised, Open label, Single-arm, Multiple ascending dose with&nbsp;patient criteria of Acute Myeloid Leukemia non eligible for intensive chemotherapy as first-line, second-line, or third-line of treatment.<\/p>\n<p>Sites targeted for this feasibility assessment were medical centers and sites located in Canada.<\/p>\n<h2>Acute Myeloid Leukemia (AML)<\/h2>\n<p>Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells with Symptoms like feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.<\/p>\n<h1>Get the Report<\/h1>\n<p>Would you like to contact these investigators and assess feasibility with them for your clinical trial?<\/p>\n<p>Please provide your email below to get detailed feasibility report on AML (Acute Myeloid Leukemia) in Canada.<\/p>\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button button-hover-2\"><a class=\"wp-block-button__link has-vivid-cyan-blue-background-color has-background\" href=\"https:\/\/credevo.com\/s\/?asp_action=show_pp&amp;product_id=2447\">Get Feasibility Report<\/a><\/div>\n<\/div>\n\n\n\n<p><em>By clicking above button, you agree with our <a href=\"https:\/\/credevo.com\/t&amp;c\">terms &amp; conditions<\/a> and <a href=\"https:\/\/credevo.com\/privacy-policy\">privacy policy<\/a><\/em><\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Share this report<\/h1>\n\n\n\n<p>Recommend this report to your friends and colleagues, who would be benefited with this readily available feasibility report.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Credevo conducted a feasibility on AML (Acute Myeloid Leukemia) and we received a great response from Investigator\/Sites. Study details The study was Phase 1 &amp; Phase 2, Interventional,&nbsp;Multi-center, Randomised, Open label, Single-arm, Multiple ascending dose with&nbsp;patient criteria of Acute Myeloid Leukemia non eligible for intensive chemotherapy as first-line, second-line, or third-line of treatment. Sites targeted [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":581,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[18],"tags":[82,81,20,84],"class_list":["post-577","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-trial-feasibility","tag-acute-myeloid-leukemia","tag-aml","tag-clinicaltrialfeasibility","tag-investigators"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acute Myeloid Leukemia (AML) - Credevo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acute Myeloid Leukemia (AML) - Credevo\" \/>\n<meta property=\"og:description\" content=\"Credevo conducted a feasibility on AML (Acute Myeloid Leukemia) and we received a great response from Investigator\/Sites. Study details The study was Phase 1 &amp; Phase 2, Interventional,&nbsp;Multi-center, Randomised, Open label, Single-arm, Multiple ascending dose with&nbsp;patient criteria of Acute Myeloid Leukemia non eligible for intensive chemotherapy as first-line, second-line, or third-line of treatment. Sites targeted [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/\" \/>\n<meta property=\"og:site_name\" content=\"Credevo\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/credevo\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-26T11:27:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-02T08:15:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"672\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Trial Expert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@gocredevo\" \/>\n<meta name=\"twitter:site\" content=\"@gocredevo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trial Expert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/\"},\"author\":{\"name\":\"Trial Expert\",\"@id\":\"https:\/\/credevo.com\/s\/#\/schema\/person\/82b65e5bccc006710d39bd446fc2a741\"},\"headline\":\"Acute Myeloid Leukemia (AML)\",\"datePublished\":\"2018-09-26T11:27:30+00:00\",\"dateModified\":\"2021-05-02T08:15:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/\"},\"wordCount\":234,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/credevo.com\/s\/#organization\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png\",\"keywords\":[\"Acute Myeloid Leukemia\",\"AML\",\"clinicaltrialfeasibility\",\"investigators\"],\"articleSection\":[\"Clinical Trial Feasibility\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/\",\"url\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/\",\"name\":\"Acute Myeloid Leukemia (AML) - Credevo\",\"isPartOf\":{\"@id\":\"https:\/\/credevo.com\/s\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png\",\"datePublished\":\"2018-09-26T11:27:30+00:00\",\"dateModified\":\"2021-05-02T08:15:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#primaryimage\",\"url\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png\",\"contentUrl\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png\",\"width\":1920,\"height\":672},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Services\",\"item\":\"https:\/\/credevo.com\/s\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acute Myeloid Leukemia (AML)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/credevo.com\/s\/#website\",\"url\":\"https:\/\/credevo.com\/s\/\",\"name\":\"Credevo\",\"description\":\"Healthcare Product Development from Clinical Development to Commercialization\",\"publisher\":{\"@id\":\"https:\/\/credevo.com\/s\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/credevo.com\/s\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/credevo.com\/s\/#organization\",\"name\":\"Credevo Pte. Ltd.\",\"url\":\"https:\/\/credevo.com\/s\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/s\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2021\/02\/logo_bw2_old.png\",\"contentUrl\":\"https:\/\/credevo.com\/s\/wp-content\/uploads\/2021\/02\/logo_bw2_old.png\",\"width\":160,\"height\":160,\"caption\":\"Credevo Pte. Ltd.\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/s\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/credevo\",\"https:\/\/x.com\/gocredevo\",\"https:\/\/www.instagram.com\/credevo_official\/\",\"https:\/\/www.linkedin.com\/company\/credevo\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/credevo.com\/s\/#\/schema\/person\/82b65e5bccc006710d39bd446fc2a741\",\"name\":\"Trial Expert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/s\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a53879903a57a96b665134a5764cd66e0f22e827a32cdfa96b8550254e77c5ad?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a53879903a57a96b665134a5764cd66e0f22e827a32cdfa96b8550254e77c5ad?s=96&d=mm&r=g\",\"caption\":\"Trial Expert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acute Myeloid Leukemia (AML) - Credevo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/","og_locale":"en_US","og_type":"article","og_title":"Acute Myeloid Leukemia (AML) - Credevo","og_description":"Credevo conducted a feasibility on AML (Acute Myeloid Leukemia) and we received a great response from Investigator\/Sites. Study details The study was Phase 1 &amp; Phase 2, Interventional,&nbsp;Multi-center, Randomised, Open label, Single-arm, Multiple ascending dose with&nbsp;patient criteria of Acute Myeloid Leukemia non eligible for intensive chemotherapy as first-line, second-line, or third-line of treatment. Sites targeted [&hellip;]","og_url":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/","og_site_name":"Credevo","article_publisher":"https:\/\/www.facebook.com\/credevo","article_published_time":"2018-09-26T11:27:30+00:00","article_modified_time":"2021-05-02T08:15:58+00:00","og_image":[{"width":1920,"height":672,"url":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png","type":"image\/png"}],"author":"Trial Expert","twitter_card":"summary_large_image","twitter_creator":"@gocredevo","twitter_site":"@gocredevo","twitter_misc":{"Written by":"Trial Expert","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#article","isPartOf":{"@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/"},"author":{"name":"Trial Expert","@id":"https:\/\/credevo.com\/s\/#\/schema\/person\/82b65e5bccc006710d39bd446fc2a741"},"headline":"Acute Myeloid Leukemia (AML)","datePublished":"2018-09-26T11:27:30+00:00","dateModified":"2021-05-02T08:15:58+00:00","mainEntityOfPage":{"@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/"},"wordCount":234,"commentCount":0,"publisher":{"@id":"https:\/\/credevo.com\/s\/#organization"},"image":{"@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#primaryimage"},"thumbnailUrl":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png","keywords":["Acute Myeloid Leukemia","AML","clinicaltrialfeasibility","investigators"],"articleSection":["Clinical Trial Feasibility"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/","url":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/","name":"Acute Myeloid Leukemia (AML) - Credevo","isPartOf":{"@id":"https:\/\/credevo.com\/s\/#website"},"primaryImageOfPage":{"@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#primaryimage"},"image":{"@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#primaryimage"},"thumbnailUrl":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png","datePublished":"2018-09-26T11:27:30+00:00","dateModified":"2021-05-02T08:15:58+00:00","breadcrumb":{"@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#primaryimage","url":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png","contentUrl":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2018\/09\/New-Project-67.png","width":1920,"height":672},{"@type":"BreadcrumbList","@id":"https:\/\/credevo.com\/s\/acute-myeloid-leukemia-aml\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Services","item":"https:\/\/credevo.com\/s\/"},{"@type":"ListItem","position":2,"name":"Acute Myeloid Leukemia (AML)"}]},{"@type":"WebSite","@id":"https:\/\/credevo.com\/s\/#website","url":"https:\/\/credevo.com\/s\/","name":"Credevo","description":"Healthcare Product Development from Clinical Development to Commercialization","publisher":{"@id":"https:\/\/credevo.com\/s\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/credevo.com\/s\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/credevo.com\/s\/#organization","name":"Credevo Pte. Ltd.","url":"https:\/\/credevo.com\/s\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/s\/#\/schema\/logo\/image\/","url":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2021\/02\/logo_bw2_old.png","contentUrl":"https:\/\/credevo.com\/s\/wp-content\/uploads\/2021\/02\/logo_bw2_old.png","width":160,"height":160,"caption":"Credevo Pte. Ltd."},"image":{"@id":"https:\/\/credevo.com\/s\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/credevo","https:\/\/x.com\/gocredevo","https:\/\/www.instagram.com\/credevo_official\/","https:\/\/www.linkedin.com\/company\/credevo"]},{"@type":"Person","@id":"https:\/\/credevo.com\/s\/#\/schema\/person\/82b65e5bccc006710d39bd446fc2a741","name":"Trial Expert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/s\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a53879903a57a96b665134a5764cd66e0f22e827a32cdfa96b8550254e77c5ad?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a53879903a57a96b665134a5764cd66e0f22e827a32cdfa96b8550254e77c5ad?s=96&d=mm&r=g","caption":"Trial Expert"}}]}},"_links":{"self":[{"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/posts\/577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/comments?post=577"}],"version-history":[{"count":11,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/posts\/577\/revisions"}],"predecessor-version":[{"id":2463,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/posts\/577\/revisions\/2463"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/media\/581"}],"wp:attachment":[{"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/media?parent=577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/categories?post=577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/credevo.com\/s\/wp-json\/wp\/v2\/tags?post=577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}